Drug intelligence / Profile preview

mCB-MSCs

Development stage: Preclinical
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

mCB-MSCs are mesenchymal stem cells derived from mouse compact bone. They are being investigated as a novel therapeutic strategy for chronic asthma. In a murine model of ovalbumin-induced chronic asthma, intravenous administration of mCB-MSCs significantly reduced histopathological changes in both distal and proximal airways, including basement membrane, epithelium, subepithelial smooth thickness, and goblet cell hyperplasia. The cells were shown to migrate to lung tissue and promote a Treg response, suggesting an immunomodulatory and regenerative mechanism of action.

Other names: compact bone-derived mesenchymal stem cells

Beyond the preview

Go deeper on mCB-MSCs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mCB-MSCs.

Explore the full profile